Adaptive Immunity to and Considerations for Vaccine Development

Overview

Journal Front Cell Infect Microbiol

Specialties Cell Biology
Infectious Diseases
Microbiology

Date 2018 Apr 24

PMID 29682484

Citations 17

Authors

Lydia M Roberts

Daniel A Powell

Jeffrey A Frelinger

Affiliations

Soon will be listed here.

Abstract

is an intracellular bacterium that causes the disease tularemia. There are several subspecies of whose ability to cause disease varies in humans. The most virulent subspecies, , is a Tier One Select Agent and a potential bioweapon. Although considerable effort has made to generate efficacious tularemia vaccines, to date none have been licensed for use in the United States. Despite the lack of a tularemia vaccine, we have learned a great deal about the adaptive immune response the underlies protective immunity. Herein, we detail the animal models commonly used to study tularemia and their recapitulation of human disease, the field's current understanding of vaccine-mediated protection, and discuss the challenges associated with new vaccine development.

Citing Articles

Marmosets as models of infectious diseases.

Herron I, Laws T, Nelson M Front Cell Infect Microbiol. 2024; 14:1340017.

PMID: 38465237 PMC: 10921895. DOI: 10.3389/fcimb.2024.1340017.

Current vaccine strategies and novel approaches to combatting Francisella infection.

Harrell J, Roy C, Gunn J, McLachlan J Vaccine. 2024; 42(9):2171-2180.

PMID: 38461051 PMC: 11095077. DOI: 10.1016/j.vaccine.2024.02.086.

Pathogenicity and virulence of .

Degabriel M, Valeva S, Boisset S, Henry T Virulence. 2023; 14(1):2274638.

PMID: 37941380 PMC: 10653695. DOI: 10.1080/21505594.2023.2274638.

Analyses of human immune responses to identify correlates of protection.

Lindgren H, Eneslatt K, Golovliov I, Gelhaus C, Sjostedt A Front Immunol. 2023; 14:1238391.

PMID: 37781364 PMC: 10540638. DOI: 10.3389/fimmu.2023.1238391.

infection model for using human lung tissue.

Koppen K, Fatykhova D, Holland G, Rauch J, Tappe D, Graff M Front Cell Infect Microbiol. 2023; 13:1224356.

PMID: 37492528 PMC: 10365108. DOI: 10.3389/fcimb.2023.1224356.

References

Crane D, Griffin A, Wehrly T, Bosio C . B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses. J Immunol. 2013; 190(6):2756-66. PMC: 3594638. DOI: 10.4049/jimmunol.1202697. View

Signarovitz A, Ray H, Yu J, Guentzel M, Chambers J, Klose K . Mucosal immunization with live attenuated Francisella novicida U112ΔiglB protects against pulmonary F. tularensis SCHU S4 in the Fischer 344 rat model. PLoS One. 2012; 7(10):e47639. PMC: 3484155. DOI: 10.1371/journal.pone.0047639. View

Conlan J, Shen H, Golovliov I, Zingmark C, Oyston P, Chen W . Differential ability of novel attenuated targeted deletion mutants of Francisella tularensis subspecies tularensis strain SCHU S4 to protect mice against aerosol challenge with virulent bacteria: effects of host background and route of immunization. Vaccine. 2009; 28(7):1824-31. PMC: 2822029. DOI: 10.1016/j.vaccine.2009.12.001. View

Woolard M, Wilson J, Hensley L, Jania L, Kawula T, Drake J . Francisella tularensis-infected macrophages release prostaglandin E2 that blocks T cell proliferation and promotes a Th2-like response. J Immunol. 2007; 178(4):2065-74. DOI: 10.4049/jimmunol.178.4.2065. View

Gillette D, Curry H, Cremer T, Ravneberg D, Fatehchand K, Shah P . Virulent Type A Francisella tularensis actively suppresses cytokine responses in human monocytes. Front Cell Infect Microbiol. 2014; 4:45. PMC: 3988375. DOI: 10.3389/fcimb.2014.00045. View

Yee D, Elkins K . Loss of either CD4+ or CD8+ T cells does not affect the magnitude of protective immunity to an intracellular pathogen, Francisella tularensis strain LVS. J Immunol. 1996; 157(11):5042-8. View

Crane D, Scott D, Bosio C . Generation of a convalescent model of virulent Francisella tularensis infection for assessment of host requirements for survival of tularemia. PLoS One. 2012; 7(3):e33349. PMC: 3299770. DOI: 10.1371/journal.pone.0033349. View

Ericsson M, Sandstrom G, Sjostedt A, Tarnvik A . Persistence of cell-mediated immunity and decline of humoral immunity to the intracellular bacterium Francisella tularensis 25 years after natural infection. J Infect Dis. 1994; 170(1):110-4. DOI: 10.1093/infdis/170.1.110. View

Stenmark S, Lindgren H, Tarnvik A, Sjostedt A . Specific antibodies contribute to the host protection against strains of Francisella tularensis subspecies holarctica. Microb Pathog. 2003; 35(2):73-80. DOI: 10.1016/s0882-4010(03)00095-0. View

10.

Cowley S, Hamilton E, Frelinger J, Su J, Forman J, Elkins K . CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med. 2005; 202(2):309-19. PMC: 2212999. DOI: 10.1084/jem.20050569. View

11.

Griffin A, Crane D, Wehrly T, Bosio C . Successful protection against tularemia in C57BL/6 mice is correlated with expansion of Francisella tularensis-specific effector T cells. Clin Vaccine Immunol. 2014; 22(1):119-28. PMC: 4278928. DOI: 10.1128/CVI.00648-14. View

12.

Carlsson H, Lindberg A, Lindberg G, HEDERSTEDT B, Karlsson K, Agell B . Enzyme-linked immunosorbent assay for immunological diagnosis of human tularemia. J Clin Microbiol. 1979; 10(5):615-21. PMC: 273233. DOI: 10.1128/jcm.10.5.615-621.1979. View

13.

Conlan J, Chen W, Shen H, Webb A, KuoLee R . Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies. Microb Pathog. 2003; 34(5):239-48. DOI: 10.1016/s0882-4010(03)00046-9. View

14.

Conlan J . Tularemia vaccines: recent developments and remaining hurdles. Future Microbiol. 2011; 6(4):391-405. DOI: 10.2217/fmb.11.22. View

15.

Cole L, Mann B, Shirey K, Richard K, Yang Y, Gearhart P . Role of TLR signaling in Francisella tularensis-LPS-induced, antibody-mediated protection against Francisella tularensis challenge. J Leukoc Biol. 2011; 90(4):787-97. PMC: 3177696. DOI: 10.1189/jlb.0111014. View

16.

Collazo C, Meierovics A, De Pascalis R, Wu T, Lyons C, Elkins K . T cells from lungs and livers of Francisella tularensis-immune mice control the growth of intracellular bacteria. Infect Immun. 2009; 77(5):2010-21. PMC: 2681748. DOI: 10.1128/IAI.01322-08. View

17.

Conlan J, Shen H, KuoLee R, Zhao X, Chen W . Aerosol-, but not intradermal-immunization with the live vaccine strain of Francisella tularensis protects mice against subsequent aerosol challenge with a highly virulent type A strain of the pathogen by an alphabeta T cell- and interferon gamma-.... Vaccine. 2005; 23(19):2477-85. DOI: 10.1016/j.vaccine.2004.10.034. View

18.

Skyberg J, Rollins M, Samuel J, Sutherland M, Belisle J, Pascual D . Interleukin-17 protects against the Francisella tularensis live vaccine strain but not against a virulent F. tularensis type A strain. Infect Immun. 2013; 81(9):3099-105. PMC: 3754213. DOI: 10.1128/IAI.00203-13. View

19.

Roberts L, Davies J, Sempowski G, Frelinger J . IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection. Vaccine. 2014; 32(29):3595-603. PMC: 4075325. DOI: 10.1016/j.vaccine.2014.05.013. View

20.

Ohara Y, Sato T, Homma M . Arthropod-borne tularemia in Japan: clinical analysis of 1,374 cases observed between 1924 and 1996. J Med Entomol. 1998; 35(4):471-3. DOI: 10.1093/jmedent/35.4.471. View